Jubilant Pharmova share price
NSE: JUBLPHARMABSE: 530019Pharmaceuticals & BiotechnologySmall Cap
Formerly Jubilant Life Sciences
Last close ₹938.30up ₹6.10 (0.65%)BSE ₹937.85
Share price at the NSE close on 23 Oct 2026. Previous close ₹932.20.
52-week range of traded prices to 23 Oct 2026
₹786.05Low, 9 Mar 2026₹1,183.00High, 4 Nov 2025
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies.
- ₹14,945 Cr422nd largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. The filing of 10 Aug 2026
- 42.4
- P/E without one-offsPrice to earnings without one-off items. Market cap divided by core profit: the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, less one-off items (exceptional items and the result of businesses sold or closed). Shown where the one-off items move that profit by more than a tenth. The last twelve months' profit includes −₹59 crore of one-off items, the largest of them in the quarter to Dec 2025.
- 36.3
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. The filing of 22 May 2026
- 2.1
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- 0.53%
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it. The filing of 10 Aug 2026
- 5.3%
- ROE without one-offsReturn on equity without one-off items. Core profit, the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders less one-off items (exceptional items and the result of businesses sold or closed), as a percentage of the same net worth as the return on equity. Shown where the one-off items move that profit by more than a tenth. The last twelve months' profit includes −₹59 crore of one-off items, the largest of them in the quarter to Dec 2025.
- 6.2%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet. The filing of 10 Aug 2026
- 7.3%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026. The filing of 22 May 2026
- 0.45
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day.
- 1,42,18342.9% delivered
Results
Consolidated; ₹ crore, the charts by years to March, the table by quarter.Quarterly results
Quarter to Jun 2026, against the quarter beforeFiled 10 Aug
- RevenueRevenue. The pill is the change in revenue against the quarter before: this period's figure divided by that one's, less one, in per cent.
- ₹2,229 Crdown 2.65%
- Net profitNet profit. The pill is the change in net profit against the quarter before: this period's figure divided by that one's, less one, in per cent.
- ₹56 Crdown 52.72%
- Net marginNet margin. Net profit as a percentage of revenue: how much of each rupee of sales is left after every cost, interest and tax.
- 2.5%
Revenue by year
Net profit by year, a loss in red
- Net profit
- Loss
A loss in 1 of the 10 years shown
The years either side of a change of basis do not compare. From the year to Mar 2021, the company's revenue for that year, ₹6,099 Cr, differs from its quarters added, ₹7,619 Cr; the company reports the part of the business demerged on 4 Feb 2021 as discontinued, and figures before the change include it.
| ₹ crore | Sep 2024Filed 28 Oct | Dec 2024Filed 31 Jan | Mar 2025Filed 12 Jun | Jun 2025Filed 29 Jul | Sep 2025Filed 31 Oct | Dec 2025Filed 6 Feb | Mar 2026Filed 22 May | Jun 2026Filed 10 Aug |
|---|---|---|---|---|---|---|---|---|
| Revenue | 1,752 | 1,822 | 1,929 | 1,901 | 1,966 | 2,123 | 2,290 | 2,229 |
| Net profit | 103 | 101 | 151 | 103 | 120 | 56 | 119 | 56 |
| Net marginNet margin. Net profit as a percentage of revenue: how much of each rupee of sales is left after every cost, interest and tax. | 5.8% | 5.5% | 7.8% | 5.4% | 6.1% | 2.6% | 5.2% | 2.5% |
Consolidated. The last eight quarters. The latest is shaded. Net profit is the whole group's, the other owners of its subsidiaries included; P/E and ROE use the company's own share.
Business segments
Share of revenue, year to Mar 2026, consolidated.Segment revenue and profit
- RadiopharmaRadiopharma, share of revenue. The segment's revenue as a percentage of the revenue of all the company's reported business segments together, leaving out eliminations between them and unallocated items.₹3,690 Crup 8.92%44.3%
- Contract Development and Manufacturing Organisation - Sterile InjectablesContract Development and Manufacturing Organisation - Sterile Injectables, share of revenue. The segment's revenue as a percentage of the revenue of all the company's reported business segments together, leaving out eliminations between them and unallocated items.₹1,813 Crup 34.00%21.7%
- Contract Research, Development and Manufacturing OrganisationContract Research, Development and Manufacturing Organisation, share of revenue. The segment's revenue as a percentage of the revenue of all the company's reported business segments together, leaving out eliminations between them and unallocated items.₹1,265 Crup 7.85%15.2%
- Allergy ImmunotherapyAllergy Immunotherapy, share of revenue. The segment's revenue as a percentage of the revenue of all the company's reported business segments together, leaving out eliminations between them and unallocated items.₹796 Crup 11.41%9.5%
- GenericsGenerics, share of revenue. The segment's revenue as a percentage of the revenue of all the company's reported business segments together, leaving out eliminations between them and unallocated items.₹774 Crup 12.87%9.3%
The pill is the change in revenue on the year before; the share is of all the businesses together.
Valuation
Today, against the company's own history. Its history crosses a change of basis in the accounts in the year to Mar 2021: days before it are of the company before the change.PE ratio and valuation history
Price to earningsPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit.
At or below today's level on 76% of 1,729 trading days over the last 10 years.
LowestHighest
Its median24.4Industry median28.1
Price to bookPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet.
At or below today's level on 56% of 1,903 trading days since Oct 2018.
LowestHighest
Its median2.0Industry median2.9
EV to EBITDAEnterprise value to EBITDA. Market cap plus borrowings less cash and bank balances, divided by operating profit before depreciation (revenue less operating expenses, without other income and one-off items) over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly): what the whole business costs against the profit its operations make. Lease liabilities are not counted: the results filings do not state them.13.9
At or below today's level on 50% of 1,093 trading days over the last 5 years.
LowestHighest
Its median13.9Industry median18.7
Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price. When a year's dividend goes ex later than the year before's, the yield reads zero for the days between; a run of under 60 such trading days is left out of the yield's medians and percentiles. The ex-date is the day from which a buyer of the share no longer gets the dividend.
At or below today's level on 46% of 2,459 trading days over the last 10 years.
LowestHighest
Its median0.56%Industry median0.51%
Where the return came from
Yearly rates to Mar 2026, per-share figures restated for splits and bonuses.
| Over | Return a year | Earnings growth | Change in P/E | Dividend yield |
|---|---|---|---|---|
| 1 year | −8.3% | −52.5% | +92.0% | 0.6% |
| 3 years | +43.7% | – | – | 0.7% |
| 5 years | +4.7% | −13.7% | +20.1% | 1.0% |
Return is price growth plus the average dividend yield. Change in P/E is (1 + price growth) / (1 + earnings growth) - 1, so the parts compound rather than add. Earnings growth and the change in P/E are left empty where earnings per share at either end of the window was a loss or is not on record. Earnings growth over 1 and 5 years includes one-off items (exceptional items and the result of businesses sold or closed) of more than a tenth of the profit of the years to Mar 2021, Mar 2025 and Mar 2026.
Mutual funds holding it
35 funds disclosed a holding for Sep 2026. What they did in Sep 2026, against each fund's month before. 11 of the 21 funds that added or cut are index funds, ETFs or arbitrage funds: an index fund or ETF holds what its index holds, and an arbitrage fund holds the share against a sale of its future.Mutual fund holdings
- Bought for the first timeBought for the first time. Funds that held it at the month's end and had not held it in any month on record before.
- 2
- AddedAdded. Funds that held more shares than at the end of the month before.
- 9
- CutCut. Funds that held fewer shares than at the end of the month before.
- 12
- Held unchangedHeld unchanged. Funds that held the same number of shares as at the end of the month before.
- 12
- Sold outSold out. Funds that held it at the end of the month before and hold none at this month's end.
- 34
| Fund | |||
|---|---|---|---|
 Bandhan Small Cap FundBandhan Mutual Fund | 48,72,987 | 1.40% | ₹501.3 Cr |
 quant Small Cap Fundquant Mutual Fund | 29,47,185 | 0.85% | ₹303.2 Cr |
 Kotak Multi Cap FundKotak Mahindra Mutual Fund | 18,28,846 | 0.62% | ₹188.2 Cr |
| Bandhan Focused FundBandhan Mutual Fund | 12,61,984 | 6.22% | ₹129.8 Cr |
 Abakkus Flexi Cap FundAbakkus Mutual Fund | 6,13,923 | 0.81% | ₹63.2 Cr |
 Aditya Birla Sun Life Small Cap FundAditya Birla Sun Life Mutual Fund | 5,00,687 | 0.84% | ₹51.5 Cr |
 HDFC Manufacturing fundHDFC Mutual Fund | 5,00,000 | 0.50% | ₹51.4 Cr |
| Abakkus Small Cap FundAbakkus Mutual Fund | 4,69,188 | 1.49% | ₹48.3 Cr |
| HDFC Pharma and Healthcare FundHDFC Mutual Fund | 3,17,568 | 0.93% | ₹32.7 Cr |
| Kotak Special Opportunities FundKotak Mahindra Mutual Fund | 2,85,765 | 1.53% | ₹29.4 Cr |
Portfolios disclosed for Sep 2026. Weight is the holding as a share of the fund's assets.
Peers and competitors
Pharmaceuticals, 216 listed companies, priced on 23 Oct 2026. The table lists the 8 companies closest to Jubilant Pharmova in market cap.
Where the company sits among the companies nearest its size
| Company | |||||||||
|---|---|---|---|---|---|---|---|---|---|
 Alivus Life SciencesALIVUS | 15,354 | 25.5 | 4.6 | 18.3 | +7.9% | +21.7% | 19.6% | 22.7% | 0.40% |
 Onesource Specialty PharmaONESOURCE | 15,299 | – | 2.6 | 48.6 | +27.2% | – | −0.8% | 0.8% | 0.00% |
 Eris LifesciencesERIS | 15,199 | 23.6 | 3.9 | 15.3 | +9.7% | +66.4% | 19.1% | 13.8% | 0.66% |
 AstraZeneca Pharma IndiaASTRAZEN | 14,971 | 88.3 | 17.2 | 63.2 | +31.1% | −7.5% | 20.6% | 24.4% | 0.60% |
 Alembic PharmaceuticalsAPLLTD | 14,941 | 21.6 | 2.6 | 13.8 | +14.1% | +14.6% | 12.7% | 11.8% | 1.58% |
 Marksans PharmaMARKSANS | 13,001 | 25.2 | 4.3 | 16.9 | – | – | 17.1% | 19.9% | 0.31% |
 Concord BiotechCONCORDBIO | 12,860 | 46.7 | 6.4 | 33.1 | −6.7% | −22.7% | 14.4% | 15.6% | 0.61% |
 CORONA RemediesCORONA | 12,545 | 63.0 | 16.8 | 39.9 | – | – | 26.6% | 30.9% | 0.49% |
Market cap in ₹ crore. Growth is the last twelve months against the twelve before. A figure is left empty where it would rest on a loss or the company has under a year of results on record. ROE is the shareholders' profit over their net worth. ROCE is profit before interest and tax over the whole group's net worth plus borrowings, as in the figures at the top of the page.
Dividends
Per share, by the year it was paid for, and the latest payments.Dividend history and dates
Dividend per share, ₹, restated for later splits and bonuses
Dividend per share. The dividends declared for the year, each restated to today's share count by the splits and bonuses after its own ex-date, added up.Highest ₹5.00 a share, in 7 years, the latest the year to Mar 2026.
| Ex-date | Type | Per share |
|---|---|---|
| 24 Jul 2026 | FinalFinal dividend. Called final by its date: the company did not say which kind it was, and it went ex within six months after the company's year end, the time in which the annual general meeting that declares the final dividend must be held. | ₹5.00 |
| 25 Jul 2025 | FinalFinal dividend. Called final by its date: the company did not say which kind it was, and it went ex within six months after the company's year end, the time in which the annual general meeting that declares the final dividend must be held. | ₹5.00 |
| 2 Aug 2024 | FinalFinal dividend. Called final by its date: the company did not say which kind it was, and it went ex within six months after the company's year end, the time in which the annual general meeting that declares the final dividend must be held. | ₹5.00 |
| 10 Aug 2023 | FinalFinal dividend. Called final by its date: the company did not say which kind it was, and it went ex within six months after the company's year end, the time in which the annual general meeting that declares the final dividend must be held. | ₹5.00 |
| 11 Aug 2022 | FinalFinal dividend. Called final by its date: the company did not say which kind it was, and it went ex within six months after the company's year end, the time in which the annual general meeting that declares the final dividend must be held. | ₹5.00 |
| 5 Aug 2021 | FinalFinal dividend. Called final by its date: the company did not say which kind it was, and it went ex within six months after the company's year end, the time in which the annual general meeting that declares the final dividend must be held. | ₹5.00 |
Latest payments, as declared, by ex-date.
Latest announcements
Routine notices left out.Share news and announcements
Oct 2026
21 Oct · Meeting
21 Oct · Rating
14 Oct · Rating
Jubilant Pharmova share price by year
Each calendar year to 2025.Jubilant Pharmova share price history
| Year | Close at year end | Change | Highest close | Lowest close |
|---|---|---|---|---|
| 2025 | 1,073.30 | −2.9% | 1,236.30 | 828.10 |
| 2024 | 1,105.20 | +102.6% | 1,262.60 | 535.25 |
| 2023 | 545.45 | +45.6% | 545.45 | 271.85 |
| 2022 | 374.75 | −36.1% | 590.15 | 313.30 |
| 2021Demerger | 586.60 | −30.6% | 1,025.60 | 558.40 |
| 2020 | 844.90 | +57.3% | 874.70 | 234.35 |
| 2019 | 537.00 | −24.4% | 873.50 | 401.80 |
| 2018 | 710.60 | −9.9% | 1,007.40 | 647.20 |
| 2017 | 788.30 | +24.7% | 853.45 | 603.90 |
| 2016 | 632.20 | +53.7% | 709.95 | 288.40 |
₹ per share, adjusted for splits and bonuses since. Change is on the close at the end of the year before. With the demerger of 4 Feb 2021 reinvested, the change in 2021 is −20.0%.
Recent sessions
The last 10 trading days to 23 Oct 2026, as traded on NSE.
| Date | Open | High | Low | Close | Average price | Volume | Delivery |
|---|---|---|---|---|---|---|---|
| 23 Oct 2026 | 932.00 | 944.80 | 895.10 | 938.30 | 919.49 | 1,42,183 | 42.9% |
| 22 Oct 2026 | 928.00 | 944.80 | 913.00 | 932.20 | 930.69 | 1,07,635 | 45.3% |
| 21 Oct 2026 | 938.20 | 938.50 | 911.60 | 929.40 | 924.04 | 1,77,629 | 48.5% |
| 19 Oct 2026 | 931.60 | 948.40 | 931.50 | 935.80 | 941.59 | 80,672 | 55.0% |
| 16 Oct 2026 | 938.20 | 954.90 | 928.60 | 938.60 | 944.87 | 1,34,966 | 53.4% |
| 15 Oct 2026 | 939.90 | 949.00 | 919.70 | 938.20 | 936.42 | 2,08,268 | 46.5% |
| 14 Oct 2026 | 945.00 | 948.90 | 928.50 | 938.90 | 938.07 | 3,91,864 | 53.0% |
| 13 Oct 2026 | 956.20 | 956.30 | 921.40 | 942.50 | 937.15 | 4,57,491 | 34.3% |
| 12 Oct 2026 | 931.90 | 969.90 | 908.00 | 950.90 | 933.72 | 14,19,970 | 59.0% |
| 9 Oct 2026 | 940.40 | 950.00 | 917.60 | 931.90 | 927.75 | 1,23,186 | 43.0% |
Prices in ₹ per share as traded, not adjusted.
Price adjustments
What the price chart is corrected for, so it reads as one share held throughout.Demerger history
| Ex-date | Event | Price factor | What happened |
|---|---|---|---|
| 4 Feb 2021 | Demerger | 0.8678 | Part of the business became a separate company. The factor is the opening price on the ex-date divided by the previous close. The chart shows earlier prices with the demerger reinvested. |
| 25 Nov 2010 | Demerger | 0.9893 | Part of the business became a separate company. The factor is the opening price on the ex-date divided by the previous close. The chart shows earlier prices with the demerger reinvested. |
Earlier prices are multiplied by the factor, so the chart reads as one share held throughout.
Company details
- Legal name
- Jubilant Pharmova Limited
- NSE symbol
- JUBLPHARMA
- BSE code
- 530019
- ISIN
- INE700A01033
- Industry
- Pharmaceuticals & Biotechnology
- Listed
- Jun 1981 on BSE, Jun 2003 on NSE
- Face value
- ₹1
- Former symbols
- JUBILANT, VAMORGANIC
- CIN
- L24116UP1978PLC004624
- Corporate identity number, the registrar of companies' code for it